Browse hierarchy: [Cardiovascular (CV)](/submissions/CV) → [Subpart B — Cardiovascular Diagnostic Devices](/submissions/CV/subpart-b%E2%80%94cardiovascular-diagnostic-devices) → [21 CFR 870.1254](/submissions/CV/subpart-b%E2%80%94cardiovascular-diagnostic-devices/870.1254) → SCZ — Percutaneous Catheter For Cutting Or Splitting Heart Valve Leaflets Concomitant To Transcatheter Valve Procedures

# SCZ · Percutaneous Catheter For Cutting Or Splitting Heart Valve Leaflets Concomitant To Transcatheter Valve Procedures

_Cardiovascular · 21 CFR 870.1254 · Class 2_

**Canonical URL:** https://fda.innolitics.com/submissions/CV/subpart-b%E2%80%94cardiovascular-diagnostic-devices/SCZ

## Overview

- **Product Code:** SCZ
- **Device Name:** Percutaneous Catheter For Cutting Or Splitting Heart Valve Leaflets Concomitant To Transcatheter Valve Procedures
- **Regulation:** [21 CFR 870.1254](/submissions/CV/subpart-b%E2%80%94cardiovascular-diagnostic-devices/870.1254)
- **Device Class:** 2
- **Review Panel:** [Cardiovascular](/submissions/CV)

## Identification

The ShortCut is a single-use, transfemoral percutaneous catheter system designed to split bioprosthetic aortic valve leaflets prior to transcatheter aortic valve replacement (TAVR). It is indicated for use in patients at risk of coronary ostium obstruction to facilitate valve-in-valve procedures. The device consists of a distal unit (with a splitting element and positioning arm), a delivery system, and a handle.

## Classification Rationale

Class II (special controls). The device is classified as Class II because it is a percutaneous catheter for cutting or splitting heart valve leaflets, and the identified risks to health can be mitigated by general controls and the specified special controls.

## Special Controls

In combination with the general controls of the FD&C Act, the percutaneous catheter for cutting or splitting heart valve leaflets concomitant to transcatheter valve procedures is subject to the following special controls:

## Recent Cleared Devices (1 of 1)

| Record | Device Name | Applicant | Decision Date | Decision |
| --- | --- | --- | --- | --- |
| [DEN240017](https://fda.innolitics.com/submissions/CV/subpart-b%E2%80%94cardiovascular-diagnostic-devices/SCZ/DEN240017.md) | ShortCut | Pi-Cardia, Ltd. | Sep 27, 2024 | DENG |

## Top Applicants

- Pi-Cardia, Ltd. — 1 clearance

---

**Source:** [https://fda.innolitics.com/submissions/CV/subpart-b%E2%80%94cardiovascular-diagnostic-devices/SCZ](https://fda.innolitics.com/submissions/CV/subpart-b%E2%80%94cardiovascular-diagnostic-devices/SCZ)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com